Q3 2024 EPS Estimates for The Joint Corp. (NASDAQ:JYNT) Lowered by Roth Capital

The Joint Corp. (NASDAQ:JYNT) – Equities researchers at Roth Capital reduced their Q3 2024 EPS estimates for shares of Joint in a research report issued on Thursday, May 2nd. Roth Capital analyst G. Kelly now anticipates that the company will post earnings per share of $0.09 for the quarter, down from their prior forecast of $0.10. The consensus estimate for Joint’s current full-year earnings is $0.13 per share. Roth Capital also issued estimates for Joint’s Q4 2024 earnings at $0.16 EPS, Q1 2025 earnings at $0.11 EPS, Q2 2025 earnings at $0.17 EPS and Q4 2025 earnings at $0.24 EPS.

Joint (NASDAQ:JYNT) last released its quarterly earnings results on Thursday, March 7th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.04. The company had revenue of $30.61 million for the quarter, compared to analyst estimates of $29.63 million. Joint had a positive return on equity of 3.76% and a negative net margin of 9.24%.

Several other brokerages also recently weighed in on JYNT. Roth Mkm reiterated a “buy” rating and issued a $16.00 price target (up from $13.00) on shares of Joint in a report on Friday. TheStreet lowered Joint from a “c-” rating to a “d” rating in a research note on Thursday, March 7th. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $23.00.

Joint Stock Performance

Shares of NASDAQ:JYNT opened at $16.12 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.08. Joint has a 12 month low of $7.31 and a 12 month high of $16.43. The company has a market capitalization of $240.83 million, a price-to-earnings ratio of -21.49 and a beta of 1.58. The firm’s 50-day moving average is $12.05 and its 200 day moving average is $10.16.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of JYNT. Barclays PLC boosted its holdings in shares of Joint by 29.4% in the 3rd quarter. Barclays PLC now owns 13,725 shares of the company’s stock valued at $123,000 after buying an additional 3,119 shares in the last quarter. Quantbot Technologies LP boosted its stake in Joint by 345.0% in the third quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock valued at $37,000 after acquiring an additional 3,233 shares in the last quarter. Bard Associates Inc. boosted its stake in Joint by 4.3% in the fourth quarter. Bard Associates Inc. now owns 79,549 shares of the company’s stock valued at $764,000 after acquiring an additional 3,250 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Joint by 43.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock worth $148,000 after purchasing an additional 4,987 shares during the last quarter. Finally, Trexquant Investment LP increased its position in shares of Joint by 8.0% during the fourth quarter. Trexquant Investment LP now owns 82,686 shares of the company’s stock worth $795,000 after purchasing an additional 6,097 shares in the last quarter. Institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.